GlassScriptPhysician profile
Habibullah Ziayee
NPI 1457610792
$2,185.25
in general payments reported to CMS, 2019-2025
32 companies · $239 in 2025
The $239 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62.28 · 2020: $289 · 2021: $490 · 2022: $331 · 2023: $413 · 2024: $361 · 2025: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $963 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $963.40 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $291.86 | 2020-2024 | |
| Stryker Corporation | $270.77 | 2020-2024 | Target |
| Ucb, INC. | $195.75 | 2021-2025 | Fintepla, Rystiggo, Briviact |
| Alexion Pharmaceuticals, INC. | $180.60 | 2022-2025 | Ultomiris |
| Jazz Pharmaceuticals INC. | $129.63 | 2023-2024 | |
| Medtronic, INC. | $126.59 | 2023-2025 | Solitaire X, Pipeline, Percept PC Brainsense |
| Medtronic USA, INC. | $106.47 | 2019-2020 | |
| Abbvie INC. | $104.49 | 2022-2025 | Botox, Ubrelvy |
| Teva Pharmaceuticals USA, INC. | $78.96 | 2021-2024 | Austedo, Austedo Xr |
| Neurelis, INC. | $74.01 | 2022-2024 | Valtoco |
| Lundbeck LLC | $73.75 | 2020-2022 | |
| Allergan, INC. | $51.08 | 2021 | |
| Pfizer INC. | $44.60 | 2023-2024 | |
| Ge Healthcare | $39.64 | 2025 | |
| Amgen INC. | $36.34 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $35.25 | 2021-2023 | Amyvid |
| Microvention, INC. | $30.89 | 2020 | |
| Merz Pharmaceuticals, LLC | $27.34 | 2024 | Inbrija, Xeomin |
| Aquestive Therapeutics, INC. | $26.90 | 2025 | |
| Biogen, INC. | $23.63 | 2025 | Skyclarys |
| Novartis Pharmaceuticals Corporation | $23.04 | 2021 | |
| Penumbra, INC. | $22.08 | 2020 | |
| Csl Behring | $22.04 | 2023 | Hizentra |
| Arbor Pharmaceuticals, INC. | $21.03 | 2021 | |
| Livanova USA, INC. | $20.65 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Greenwich Biosciences, INC. | $20.45 | 2020 | |
| Argenx US, INC. | $20.10 | 2024 | Vyvgart Hytrulo |
| Upsher-Smith Laboratories LLC | $19.96 | 2021 | |
| Viz.Ai, INC. | $19.73 | 2022 | |
| Xeris Pharmaceuticals, INC. | $19.07 | 2023 | Keveyis |
| Biohaven Pharmaceutical Holding Company LTD. | $15.25 | 2022 | |
| Celgene Corporation | $13.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Habibullah Ziayee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.